[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fulcrum Therapeutics Inc (FULC)

Fulcrum Therapeutics Inc (FULC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 245,876
  • Shares Outstanding, K 66,633
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,880 K
  • EBIT $ -87 M
  • EBITDA $ -85 M
  • 60-Month Beta 2.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.67

Options Overview Details

View History
  • Implied Volatility 72.24% (-42.25%)
  • Historical Volatility 212.97%
  • IV Percentile 2%
  • IV Rank 5.17%
  • IV High 299.91% on 03/03/26
  • IV Low 59.82% on 06/03/26
  • Expected Move (DTE 9) 0.38 (11.12%)
  • Put/Call Vol Ratio 2.97
  • Today's Volume 1,097
  • Volume Avg (30-Day) 1,123
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 27,131
  • Open Int (30-Day) 15,026
  • Expected Range 3.06 to 3.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.22
  • Number of Estimates 7
  • High Estimate $-0.04
  • Low Estimate $-0.26
  • Prior Year $-0.28
  • Growth Rate Est. (year over year) +21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.83 +21.55%
on 06/02/26
7.50 -54.13%
on 05/11/26
-3.57 (-50.93%)
since 05/08/26
3-Month
2.83 +21.55%
on 06/02/26
8.37 -58.90%
on 04/20/26
-4.73 (-57.89%)
since 03/06/26
52-Week
2.83 +21.55%
on 06/02/26
15.74 -78.14%
on 12/08/25
-3.81 (-52.55%)
since 06/06/25

Most Recent Stories

More News
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud

Fulcrum Therapeutics, Inc. lost approximately half its market value after disclosing FDA safety concerns leading the company to discontinue its lead sickle-cell candidate.*

FULC : 3.44 (-6.78%)
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations

SEC filings reflected insider equity holdings and awards totaling more than 264,000 shares

FULC : 3.44 (-6.78%)
Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 million facility lease locked the company into infrastructure now stranded by program termination.

FULC : 3.44 (-6.78%)
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk...

FULC : 3.44 (-6.78%)
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...

FULC : 3.44 (-6.78%)
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive...

FULC : 3.44 (-6.78%)
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve...

FULC : 3.44 (-6.78%)
Can Fulcrum Therapeutics Translate Pociredir Trial Data Into Revenue Momentum?

Barchart Research What to Expect from FULC Earnings FULC Generated April 24, 2026 Current Price $7.84 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 9.72% Can Fulcrum Therapeutics Translate...

FULC : 3.44 (-6.78%)
Can Fulcrum Therapeutics Translate Pociredir Trial Data Into Revenue Momentum?

Barchart Research What to Expect from FULC Earnings FULC Generated April 24, 2026 Current Price $7.84 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 9.72% Can Fulcrum Therapeutics Translate...

FULC : 3.44 (-6.78%)
Can Fulcrum Therapeutics Translate Pociredir Trial Data Into Revenue Momentum?

Barchart Research What to Expect from FULC Earnings FULC Generated April 24, 2026 Current Price $7.84 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 9.72% Can Fulcrum Therapeutics Translate...

FULC : 3.44 (-6.78%)

Business Summary

Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 3.86
2nd Resistance Point 3.75
1st Resistance Point 3.59
Last Price 3.44
1st Support Level 3.32
2nd Support Level 3.21
3rd Support Level 3.05

See More

52-Week High 15.74
Fibonacci 61.8% 10.81
Fibonacci 50% 9.28
Fibonacci 38.2% 7.76
Last Price 3.44
52-Week Low 2.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.